Author(s)

Gang Liang, Zemuyuan Zhang, Yanchen Zhou

Corresponding Author

Zemuyuan Zhang

ABSTRACT

Fostemsavir (Rukobia, ViiV Healthcare), is a prodrug of temsavir, an uncommon pyridine complicates with cogent liveliness against HIV-1. Fostemsavir, the first nuncupative attachment inhibitor, was ratified and granted the therapy designation by the Food and Drug Administration (FDA) for use in association with other antiretroviral agents for the treatment of HIV-1 infection in adults. As absorption of temsavir is not altered with increased gastric pH, patients may take acidic concealing agents such as famotidine during fostemsavir therapy.Temsavir is primarily metabolized through hydrolysis but also via cytochrome P-450 (CYP) oxygenation; therefore, coadministration of fostemsavir with firm CYP3A inducers such as rifampin, carbamazepine, phenytoin, mitotane, enzalutamide, or St John’s plant is contraindicated because it may result in significantly lower temsavir exposure, which can eventually impair virologic response. The most common adverse reactions combined with fostemsavir use embody nausea, scour, bother, abdominal smart, indigestion, labor, rash, and sleep disturbance.

KEYWORDS

Component, Fostemsavir, Rukobia, HIV-1, BRIGHT, ViiV